Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on August 22, 2018, covering events occurring on August 17, 2018. The filing addresses a significant change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
- Departure of Chief Financial Officer: Robert E. Gagnon submitted his resignation from all positions, including CFO, effective August 31, 2018.
- Reason for Departure: The filing explicitly states that Mr. Gagnon did not resign for any reasons related to the Company's accounting practices or financial statements.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed in this report other than the standard disclosure of the executive departure.
Investor Verification Checklist
- Verify the appointment of an interim or permanent replacement for the CFO position.
- Review the attached press release (Exhibit 99.1) for additional context on the transition plan.
- Confirm that no undisclosed accounting issues exist, despite the explicit denial in the filing.